医学
人类免疫缺陷病毒(HIV)
病毒学
疾病
免疫学
内科学
作者
Fredrik O Vannberg,Joann M. McDermid,Assan Jaye
摘要
To the Editor: Esbjornsson and colleagues (July 19 issue)1 conclude that infection with human immunodeficiency virus type 2 (HIV-2) attenuates the course of HIV-1 infection. Their report raises three issues. First, in Guinea-Bissau, up to 30% of persons infected with both HIV-1 and HIV-2 have coinfection with human T-cell lymphotropic virus type 1 (HTLV-1),2 a circumstance that leads to an increased percentage of CD4+ T cells.3 The authors did not control for coinfection with HTLV-1, a condition that may well have contributed to the high percentage of CD4+ T cells among persons with dual HIV infection. Second, despite the study’s long follow-up time, the authors did not treat age as a time-dependent variable in the Cox regression analyses; failure to have done so may have led to the appearance of a reduction in the rate of disease progression. In a recently published survival analysis (including 70 participants with dual HIV infection who were followed for 20 years) in which age was treated as a time-dependent variable, no differences in mortality were observed between participants with HIV-1 infection only and those with dual infection.4 Finally, none of six studies comparing mortality rates between participants with HIV-1 infection only and participants with dual infection reported lower mortality among participants with dual infection (see the figure published with the full text of this letter at NEJM.org)5; the findings of Esbjornsson and colleagues seem to be at odds with the findings in these studies and with the fact that HIV-2 infection does not affect HIV-1 viral load in persons with dual infection.5 Carla van Tienen, M.D., Ph.D. Erasmus Medical Center Rotterdam, the Netherlands c.vantienen@erasmusmc.nl
科研通智能强力驱动
Strongly Powered by AbleSci AI